{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:25:44Z","timestamp":1793276744328,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.euros.2022.04.015","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T18:25:43Z","timestamp":1654107943000},"page":"105-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Gu\u00e9rin\u2013unresponsive Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6929-6124","authenticated-orcid":false,"given":"Girish S.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Lilge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nesbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Dumoulin-White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkady","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.S.","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2022.04.015_b0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.euf.2018.11.005","article-title":"Risk stratification tools and prognostic models in non-muscle invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel","volume":"6","author":"Soukup","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2022.04.015_b0010","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1756287215599694","article-title":"Management of carcinoma in situ of the bladder: best practice and recent developments","volume":"7","author":"Tang","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euros.2022.04.015_b0015","unstructured":"Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. https:\/\/www.fda.gov\/media\/101468\/download."},{"key":"10.1016\/j.euros.2022.04.015_b0020","doi-asserted-by":"crossref","first-page":"323157","DOI":"10.1155\/2015\/323157","article-title":"Complications of radical cystectomy and orthotopic reconstruction","volume":"2015","author":"Tan","year":"2015","journal-title":"Adv Urol"},{"key":"10.1016\/j.euros.2022.04.015_b0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2022.04.015_b0030","unstructured":"U.S. Food and Drug Administration. FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer."},{"key":"10.1016\/j.euros.2022.04.015_b0035","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0090-4295(99)80080-6","article-title":"Long-term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder","volume":"45","author":"D\u2019Hallewin","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.euros.2022.04.015_b0040","first-page":"250","article-title":"Photodynamic therapy of cancer: an update","volume":"61","author":"Agostinis","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euros.2022.04.015_b0045","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","article-title":"Photodynamic therapy \u2013 mechanisms, photosensitizers and combinations","volume":"106","author":"Kwiatkowski","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.euros.2022.04.015_b0050","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/107327481402100304","article-title":"Phase 1 trial design: is 3+3 the best?","volume":"21","author":"Hansen","year":"2014","journal-title":"Cancer Control"},{"key":"10.1016\/j.euros.2022.04.015_b0055","doi-asserted-by":"crossref","first-page":"e001926","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future [published correction appears in J Immunother Cancer 2021 Oct; 9(10):]","volume":"9","author":"Alzeibak","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euros.2022.04.015_b0060","doi-asserted-by":"crossref","first-page":"e1900927","DOI":"10.1002\/adma.201900927","article-title":"Light-triggered in situ gelation to enable robust photodynamic-immunotherapy by repeated stimulations","volume":"31","author":"Meng","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.euros.2022.04.015_b0065","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Cancer Therapy Evaluation Program (CTEP). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"10.1016\/j.euros.2022.04.015_b0070","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10928-014-9392-y","article-title":"Searching for an optimal AUC estimation method: a never-ending task?","volume":"41","author":"Wojciech","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.euros.2022.04.015_b0075","unstructured":"Nseyo UO. Sequential whole bladder photodynamic therapy (WBPDT) in the management of superficial bladder cancer. Clinicaltrials.gov identifier: NCT00322699. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00322699?view=record."},{"key":"10.1016\/j.euros.2022.04.015_b0080","doi-asserted-by":"crossref","unstructured":"Mejia MC, Nseyo UO. Safety of three sequential whole bladder photodynamic therapy (WBPDT) treatments in the management of resistant bladder cancer. Photonic Therapeutics and Diagnostics V; 71611P. 2009. Progress in Biomedical Optics and Imaging\u2014Proceedings of SPIE. 7161.","DOI":"10.1117\/12.806893"},{"key":"10.1016\/j.euros.2022.04.015_b0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1039\/c5pp00450k","article-title":"A ruthenium(II) based photosensitizer and transferrin complexes enhance photo-physical properties, cell uptake, and photodynamic therapy safety and efficacy","volume":"15","author":"Kasper","year":"2016","journal-title":"Photochem Photobiol Sci"},{"key":"10.1016\/j.euros.2022.04.015_b0090","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/acs.chemrev.8b00211","article-title":"Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433","volume":"119","author":"Monro","year":"2019","journal-title":"Chem Rev"},{"key":"10.1016\/j.euros.2022.04.015_b0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ccr.2014.04.012","article-title":"Ru(II) dyads derived from \u03b1-oligothiophenes: a new class of potent and versatile photosensitizers for PDT","volume":"282\u20133","author":"Shi","year":"2015","journal-title":"Coord Chem Rev"},{"key":"10.1016\/j.euros.2022.04.015_b0100","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.1021\/acs.inorgchem.6b01782","article-title":"Theoretical exploration of type I\/type II dual photoreactivity of promising Ru(II) dyads for PDT approach","volume":"55","author":"Alberto","year":"2016","journal-title":"Inorg Chem"},{"key":"10.1016\/j.euros.2022.04.015_b0105","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1593\/neo.09284","article-title":"Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer","volume":"11","author":"Srikrishna","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.euros.2022.04.015_b0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2022.04.015_b0115","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168322005900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168322005900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:07:48Z","timestamp":1762978068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168322005900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":23,"alternative-id":["S2666168322005900"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2022.04.015","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1b Clinical Study of Intravesical Photodynamic Therapy in Patients with Bacillus Calmette-Gu\u00e9rin\u2013unresponsive Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2022.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}